Boston Yasmin-Yaz-Ocella Attorney

In 2001 the FDA approved Bayer HealthCare Pharmaceutical’s new birth control drug Yasmin. Unlike prior hormonal birth control drugs, Yasmin contained drospirenone which is believed to cause the major side effects associated with Ocella, Yasmin and Yaz. Studies published in the British Medical Journal in October 2011 revealed that users of birth controls Ocella, Yasmin and Yaz were twice as likely to develop serious injuries than they were had they not taken these drugs. After hitting the market in 2006, Yaz became widely popular as a medicine to prevent pregnancy as well as treat acne and premenstrual syndrome (PMS). Yasmin is Bayer HealthCare Pharmaceutical’s low dose version of the medicine. The generic version is Ocella which is manufactured by Barr Laboratories and marketed by Teva Pharmaceuticals.

Due to the severe side effects associated with these drugs, including blood clots, deep vein thrombosis, strokes, cardiac arrhythmia and sudden death (amongst others), lawsuits have been filed alleging false advertising, misrepresentation, failure to warn, negligence, and products liability. Claims alleged Bayer HealthCare Pharmaceuticals performed inadequate product testing and development before marketing these drugs for profit.

If you or a loved one have suffered from an injury caused by Ocella, Yasmin, or Yaz, please call Sweeney Merrigan Law to speak with a knowledgeable and trustworthy attorney.

Statute of Limitations

If you or someone you know has taken Ocella, Yaz or Yasmin and have been caused to suffer serious negative side effects (blood clots, deep vein thrombosis, strokes, cardiac arrhythmia or sudden death), there is a time limit on how long you have to pursue your case called the Statute of Limitations. The Statute of Limitations is different in each state. Therefore, if you or someone you know has suffered the serious negative side effects caused by taking Ocella, Yaz or Yasmin, have them contact an attorney at Sweeney Merrigan Law at (617)-391-9001 for a case evaluation before it’s too late.